CRL

Business Context and Reporting Period

Company: Charles River Laboratories International, Inc. (CRL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended December 27, 2025
Business Overview: A leading global non-clinical drug development partner providing research models, discovery and safety assessment services, and manufacturing solutions. The company operates in over 120 sites across 20+ countries.
Segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Decline: Operating income dropped 88.9% year-over-year, primarily driven by significant impairment charges and lower revenue in the DSA segment.
• Impairment Charges: The company recorded $376.0 million in total impairment charges in 2025, including:
  • Goodwill Impairment: $165.0 million in the Manufacturing segment (Biologics Solutions reporting unit).
  • Intangible Asset Impairment: $211.0 million across RMS (Cell Solutions) and Manufacturing (CDMO Gene Therapy) segments.
  • Long-Lived Asset Impairment: Approximately $8.0 million in property, plant, and equipment.
• Segment Performance:
  • RMS: Revenue increased 2.0% to $846.1 million, but operating income fell 61.0% due to a $102.0 million intangible asset impairment.
  • DSA: Revenue decreased 2.0% to $2.40 billion due to cautious client spending; operating income declined 4.1%.
  • Manufacturing: Revenue was flat (-0.4%), but the segment reported an operating loss of $184.3 million (vs. $71.5 million loss in 2024) due to impairments and accelerated amortization.
• Restructuring: Incurred $99.8 million in restructuring charges, down from $107.0 million in 2024, focused on workforce right-sizing and site consolidation.

Guidance, Outlook, and Risks

• Strategic Review: The Board is conducting a comprehensive strategic review, planning to divest non-core assets representing approximately 7% of 2025 revenue and pursue strategic acquisitions to strengthen core markets.
• Cost Savings: Initiatives are expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026.
• Leadership Transition: CEO James C. Foster will retire effective May 5, 2026, with COO Birgit Girshick appointed as the successor.
• Recent Acquisitions: Completed the acquisition of K.F. (Cambodia) Ltd. assets ($510 million) in January 2026 to secure non-human primate (NHP) supply. Exercised option to acquire remaining interest in PathoQuest SAS (approx. $60 million).
• Key Risks:
  • NHP Supply Chain: Continued reliance on limited sources for non-human primates, though USFWS clearance for Cambodian imports was received in November 2025.
  • Legal Proceedings: A putative securities class action regarding NHP import disclosures remains pending after an appellate court reversed a dismissal in August 2025. Two derivative lawsuits are stayed pending the class action outcome. The SEC investigation concluded in November 2025 with no enforcement action recommended.
  • Market Demand: Cautious spending by biopharmaceutical clients and potential shifts toward New Approach Methodologies (NAMs) reducing animal testing.

Investor Verification Checklist

• Impairment Sustainability: Verify if the $376 million in impairment charges are one-time events or indicative of ongoing asset devaluation in the Biologics and CDMO segments.
• NHP Supply Stability: Confirm the operational integration of the K.F. (Cambodia) acquisition and the long-term reliability of the NHP supply chain post-USFWS clearance.
• Legal Exposure: Monitor the status of the securities class action lawsuit and potential settlement costs, as the company cannot currently estimate the range of loss.
• Restructuring Execution: Track the realization of the projected $300 million in annualized cost savings and the impact of the planned divestitures (7% of revenue).
• Leadership Continuity: Assess the impact of the CEO transition scheduled for May 2026 on strategic execution and investor relations.